The Quantellect read.As of Nov 19, 2026, 5 active firms cover Chemed Corp: 2 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $475.00 to $650.00, so the covering firms are broadly aligned. The average target of $554.60 sits 1% above the current $546.69. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $6.10 next quarter toward $27.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Neutral
Strong Buy00%
Buy240%
Neutral360%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$554.60
+1.4% upside
Average target across 5 active firms as of Nov 19, 2026 vs $546.69 current
Highest Target$650.00
Average Target$554.60
Lowest Target$475.00
Detailed analyst forecasts for CHE
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 2 of 5 active firms rate CHE a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CHE EPS & revenue forecast
EPS · NEXT QUARTER
$6.10
Range $5.96 – $6.34 · 3 analysts · +8% YoY
Next period, 3 analysts expect Chemed Corp to earn $6.10 a share (range $5.96 – $6.34), versus $5.65 a year earlier. Full-year consensus is $25.78, growing to $27.85 the year after.
REVENUE · NEXT QUARTER
$712.9M
Range $706.2M – $726.1M · 3 analysts · +8% YoY
Revenue is expected to reach $712.9M (range $706.2M – $726.1M), +8.4% year-over-year. Full-year consensus is $2.7B, rising to $2.9B next year.
Top analysts covering Chemed Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CHE.
#1
Ben Hendrix
RBC Capital · Rank #150
Neutral
$548.00+0.2% to target
Overall win rate
44%
+ Follow
#2
Brian Tanquilut
Jefferies · Rank #280
Buy
$620.00+13.4% to target
Overall win rate
46%
+ Follow
#3
AR
A.J. Rice
UBS · Rank #365
Buy
$650.00+18.9% to target
Overall win rate
35%
+ Follow
#4
Michael Wiederhorn
Oppenheimer
Buy
$590.00+7.9% to target
Coverage
—
+ Follow
#5
Joanna Gajuk
B of A Securities
Neutral
$510.00-6.7% to target
Coverage
—
+ Follow
CHE stock forecast FAQ
What is CHE's average 12-month price target?+
The 5 active firms with a live target average $554.60 for Chemed Corp over the next 12 months, ranging from a $650.00 high to a $475.00 low, as of Nov 19, 2026.
Is CHE stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 5 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CHE?+
The Street-high target is $650.00 (UBS), and the Street-low is $475.00 (Jefferies). The average of all 5 active-firm targets is $554.60.
How many active Wall Street firms cover CHE?+
5 active firms have a recognized rating on Chemed Corp as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CHE?+
Among analysts who currently cover CHE, Ben Hendrix of RBC Capital has the strongest overall Quantellect track record (Rank #150). Their current call is Neutral with a $548.00 target.
What is Chemed Corp's projected EPS for next quarter?+
The consensus estimate is $6.10 per share (range $5.96 – $6.34) across 3 analysts. Full-year EPS is projected at $25.78, rising to $27.85 the following year.
How much revenue is Chemed Corp expected to report next quarter?+
Consensus revenue is $712.9M (range $706.2M – $726.1M). Full-year revenue is projected at $2.7B, growing to $2.9B next year.
Have analysts been upgrading or downgrading CHE lately?+
As of Nov 19, 2026, 2 of 5 active firms rate CHE a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CHE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.